ARTICLES BY SUZANNE ELVIDGE

• The Strength At The Interface: Academia Meets Biopharma Industry

  7/31/2014

  Collaborations between academia and industry are becoming more common as biopharma companies, both large and small, see the value gained from different approaches.

• Why You Should Consider Automated In Vivo Sampling Systems

  7/11/2011

  While in vitro studies are becoming more accurate and the resulting preclinical data more likely to predict the clinical activity of a drug, in vivo studies (studies in animals) are still vital for the assessment of pharmacokinetics and drug metabolism and essential for approval of drugs and devices by regulatory bodies. By Suzanne Elvidge, Life Science Leader magazine

• The Next Biopharma Business Model

  11/13/2009

  One of the biggest costs for the biopharma industry is that of drug R&D. “I’ve worked in the biopharma industry for more than 25 years, and I felt that the R&D sector was underperforming,” says Ulrich Grau, Ph.D., president, CEO, and cofounder of Lux Biosciences. By Suzanne Elvidge, Life Science Leader magazine